New Insight with Dr. Veeral Sheth

Diabetes Dialogue

Don’t Miss a Beat

Crisis Point

Tim Smith joined the MJH Life Sciences team as an assistant editor for HCPLive in August 2022. He graduated from UC Berkeley with a degree in political science, working in multimedia journalism as a staff writer prior to joining MJH. In his spare time, he enjoys reading, watching TV, listening to podcasts, and rock climbing. You can contact him at 

This ACP Conference interview featured a discussion with Inouye about gaps in knowledge regarding patients experiencing delirium during hospitalization.

Sharon K. Inouye, MD, MPH: Why is Delirium During Hospitalization Not Taken Seriously?

In another segment of her interview at the 

2024 American College of Physicians (ACP) Internal Medicine Meeting

 in Boston, Sharon K. Inouye, MD, MPH, MCAP, delved further into the major talking points of her presentation ‘Delirium During Hospitalization.’

Inouye is known for her work as professor of medicine at Harvard Medical School, as well as her work as Milton and Shirley F. Levy Family chair and director of the Aging Brain Center of the Hinda and Arthur Marcus Institute for Aging Research. Additionally, Inouye serves as editor-in-chief of JAMA Internal Medicine.

, Inouye had detailed some of the major takeaways from her discussion, highlighting changes over time that have occurred in teaching medical students and clinicians about the serious problem of delirium faced by many older adults who have been hospitalized. Here, she was asked about what is keeping assessments of delirium from being more widely implemented.

“I think the reason people say they can't do it is they claim they don't have time,” Inouye said. “But now we've created this ultra-brief assessment method, widely available and free of charge. We feel like we're eliminating that excuse, but people don't know about it. Spreading the word, I think, is really, really important.”

Inouye expressed that she hoped ACP could circulate the assessment widely so that, at least, the message about the use of the assessment is known more widely to internists.

“The other part of it is that, I think you're right, there isn’t an imperative to recognize delirium,” Inouye explained. “Because people, first of all, don't realize it's preventable. People often think, ‘oh, there's nothing to do once an older person becomes confused or anybody becomes confused.’ But there is so much to be done in terms of both optimizing care…nutrition, hydration, making sure that the person is getting mobilized and ready to go home as soon as possible.”

Inouye added that laboratories must also not be in disarray and that medical conditions are under control. She noted that delirium is often a barometer for other things going wrong, which Inouye believes many clinicians do not accept or fully understand.

“There's still some of this thinking that I told you I experienced 35 years ago, thinking ‘well, delirium is just inevitable and it's just going to happen to older adults when they're sick, so there's nothing that can be done.’ We really want to counter that thinking. And I think more and more hospitals are realizing this and they're starting to realize that these patients who get confused in the hospitals are costing them a lot of money.”

For additional information on the presentation topic, view the full interview segment posted above. Other 

The quotes contained in this interview were edited for the purposes of clarity.


Videos

Internal Medicine

Internal Medicine condition center page, resources on the topics of medical news and expert insight into internal medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on internal medicine research, treatment, and drug development.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease.

Understanding Biologics for Patients With IBD

In discussing the issue of inflammatory bowel disease (IBD) in patients receiving IL-17 blockers, the experts acknowledge the cautionary language in package inserts based on early studies. While there was initial concern about potential exacerbation of IBD with IL-17 blockers, subsequent real-world data have not shown increased or worsened IBD symptoms. Their approach to managing patients with a history of or suspected IBD involves thorough screening, including personal and family history, and symptoms such as bloody stools or nocturnal bowel movements. They also highlight the importance of distinguishing between irritable bowel syndrome (IBS) and IBD, as patients may confuse the two.

Despite the low prevalence of IBD in psoriasis patients and the relatively rare occurrence of IBD exacerbation with IL-17 blockers, the dermatologists exercise caution, particularly in patients with a confirmed diagnosis of IBD. They may avoid prescribing IL-17 blockers in such cases or closely monitor patients with a family history of Crohn's disease. While acknowledging the rarity of IBD exacerbation with IL-17 blockers, the experts prioritize patient safety and consider alternative biologic options for individuals with a history of or increased risk for IBD, including TNF blockers or other targeted therapies. Their approach reflects a balanced assessment of available evidence and individual patient factors to optimize treatment outcomes while minimizing potential risks.

Video synopsis is AI-generated and reviewed by HCPLive® editorial staff.

Peer Exchange

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.

Infectious Diseases and Biologic Treatment Selection

In patients with a positive test for tuberculosis (TB), the experts discuss their approach to treatment initiation with IL-17 and IL-23 blockers. They note that while TB monitoring remains a standard practice, the risk of TB reactivation with these biologics is low based on available evidence. Annual TB testing is not routinely recommended after treatment initiation due to the lack of signal for TB reactivation in meta-analyses of IL-17 and IL-23 blockers.

Regarding patients with a positive TB test and negative chest X-ray, they emphasize the importance of individualized patient care and collaboration with infectious disease specialists. Waiting for TB prophylaxis to take effect, typically four weeks, before starting systemic agents for psoriasis is considered prudent; in urgent cases such as active psoriatic arthritis, treatment initiation may be expedited. For patients with active TB, the experts recommend initiating anti-TB treatment and waiting before considering systemic biologic therapy. They highlight the need to adhere to label recommendations, which advise against starting biologics during active infections. Overall, their approach prioritizes patient safety and adherence to established guidelines while ensuring timely and effective management of psoriasis and psoriatic arthritis.

Experts emphasize the importance of collaboration with infectious disease specialists for patients with tuberculosis, while highlighting the low reactivation rates in newer agents.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

TJ Chao and Kristine Kucera, PA’s discuss the changing treatment algorithms of plaque psoriasis with the arrival of novel agents such as the TYK2 inhibitors. 

Impact of the expanding treatment landscape on the treatment algorithm of plaque psoriasis 

In this series, dermatologists TJ Chao and Kristine Kucera delve into recent developments in plaque psoriasis treatment, including the emergence of TYK2 inhibitors. They highlight the evolving role of physician assistants in managing plaque psoriasis and discuss its recognition as a systemic disease. The conversation covers lab and monitoring requirements for TYK2 inhibitors like deucravacitinib, alongside a review of short- and long-term clinical trial data. Chao and Kucera offer insights into patient selection and the patient experience with oral systemic agents, providing guidance for selecting appropriate therapies in the expanding treatment landscape.

This summary was AI-generated and edited for clarity.

Ophthalmology

Ophthalmology page, resources on the topics of medical news and expert insight into ophthalmic disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on eye disease research, treatment, and drug development.

Impact of the Expanding Treatment Landscape on the Treatment Algorithm of Plaque Psoriasis

Providers in rheumatology, dermatology and gastrointestinal disease how they are selecting between the various adalimumab biosimilars available patients.

Selecting Between Adalimumab Biosimilars for Your Patients

This is a video synopsis/summary of a panel discussion involving Jamie T. Brogan, MSN, APRN, FNP-BC; Kostas Botsoglou, MD; Jordan Axelrad, MD, MPH; Sophia Humphreys, PharmD, MHA; and Peter Lio, MD.

The discussion revolves around how to choose the appropriate biosimilar for patients. In dermatology, options are limited, especially for conditions like psoriasis where newer treatments may outperform existing biosimilars. However, for conditions like hidradenitis, where choices are scarce, biosimilars offer a straightforward solution. The growth of biosimilars is anticipated to provide more options for clinicians, allowing them to select treatments based on efficacy and patient insurance coverage.

Clinicians often consider insurance formularies to anticipate the most easily approved biosimilar for each patient. In conditions like inflammatory bowel disease (IBD), certain biologics like Adalimumab play a significant role in treatment, leading to the proliferation of biosimilars. While payer preferences often influence prescribing decisions, clinicians prioritize factors like citrate-free formulations, small volume, high concentration, and robust patient support programs when choosing biosimilars, aiming for broader uptake and patient adherence.

Video synopsis is AI-generated and reviewed by HCPLive editorial staff.

Providers in rheumatology, dermatology and gastrointestinal disease talk about how they are selecting between the various adalimumab biosimilars available for their patients.

Biosimilars

Abigail Brooks is an assistant editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Articles

In recognition of World IBS Day, we spoke with Jeffrey Roberts about what led him to found the holiday in 2019 and took a closer look at the continued marginalization of the condition.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

Putting Patients First: Breaking Stigma, Dispelling Misconceptions to Improve IBS Care

A clinical pharmacist and specialists in rheumatology, dermatology, and gastrointestinal disease share strategies in how to increase the uptake of adalimumab biosimilar among providers.

Strategies to Increase Adalimumab Biosimilar Uptake in Clinical Practice

Advances practice providers in dermatology discuss the safety data on the novel TYK2 inhibitor deucravacitnib. 

Safety Data on Deucravacitinib

Dermatologists Drs Tina Bhutani and Scott Boswell and patient Kanya Oul discuss unpredictable nature of generalized pustular psoriasis (GPP) and management of flares and GPP between flares.

Unpredictable Nature of Generalized Pustular Psoriasis (GPP) and Treatment

Dermatologists Drs Tina Bhutani and Scott Boswell discuss use of spesolimab to treat generalized pustular psoriasis (GPP) flares.

Spesolimab for Treatment of Generalized Pustular Psoriasis (GPP) Flares

During this Q&A interview, Crandall discussed the takeaways from her portion of an ACP conference presentation on current clinical guidelines in type 2 diabetes.


Type 2 Diabetes

Carolyn J. Crandall, MD: Key Guideline Updates for Type 2 Diabetes

In this interview at the ACP conference, Inouye discussed some of the major reasons for her presentation titled ‘Delirium During Hospitalization.’

Discussing Delirium During Hospitalization with Sharon K. Inouye, MD, MPH

Lana Pine is the editor of HCPLive Rheumatology. She is an experienced editor and technical writer with a demonstrated history of working in the banking and publishing industries. In her free time, she enjoys cooking, yoga, listening to podcasts, and drawing. She can be reached via email at LPine@mjhlifesciences.com.

Most (94%) anti-nucleocapsid positivity was linked to a self-reported COVID-19 infection within the prior 3 months. 

Rheumatoid Arthritis

The HCPLive rheumatoid arthritis page is a comprehensive resource for clinical news and insights on arthritis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for RA, and more.

COVID-19

COVID-19 page, resources on the topics of medical news and expert insight into coronavirus can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COVID-19 research, treatment, and drug development.

Study Investigates Optimal COVID-19 Vaccination Timing in Inflammatory Disease

Connor Iapoce is an associate editor for 

 and joined the MJH Life Sciences team in April 2021. He graduated from The College of New Jersey with a degree in Journalism and Professional Writing. He enjoys listening to records, going to concerts, and playing with his cat Squish. You can reach him at 

Elna Saah, MD joins HCPLive to discuss the current landscape in sickle cell disease and recent advancements benefiting clinical care.

Hematology

Sickle Cell

Sickle Cell condition center page, resources on the topics of medical news and expert insight into sickle cell disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sickle cell research, treatment, and drug development.

Elna Saah, MD: Unraveling the Current Landscape in Sickle Cell Disease

Modern large language models perform strongly on ophthalmic knowledge assessments and approach or exceed the scores of fully qualified and trainee ophthalmologists.

Latest News

Sharon K. Inouye, MD, MPH: Why is Delirium During Hospitalization Not Taken Seriously?

Understanding Biologics for Patients With IBD

Infectious Diseases and Biologic Treatment Selection

Impact of the Expanding Treatment Landscape on the Treatment Algorithm of Plaque Psoriasis

Selecting Between Adalimumab Biosimilars for Your Patients